Editor's Highlights—February 2026
International Journal of Dermatology · 2026
DOI: 10.1111/ijd.70248 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Lajos Kemény. Beteiligte Einrichtung: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Psoriasis, Hidradenitis Suppurativa. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
The February issue of the IJD reflects the growing complexity of managing chronic inflammatory skin diseases in the era of targeted therapies. Covering atopic dermatitis, psoriasis, and hidradenitis suppurativa, the featured papers address clinically relevant questions related to treatment safety, disease‐associated comorbidities, and long‐term therapeutic outcomes. Key topics include vaccination strategies in patients receiving Janus kinase inhibitors, ocular complications associated with atopic dermatitis, malignancy considerations in biologic‐treated psoriasis, long‐term efficacy and safety of selective tyrosine kinase 2 (TYK2) inhibition, and dose optimization of biologic therapy in hidradenitis suppurativa. Together, these contributions highlight a shift toward personalized, risk‐aware management strategies that balance sustained efficacy with long‐term safety in chronic inflammatory dermatoses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
ORCID-Profile: Lajos Kemény
Zitieren
APA
Kemény, L. (2026). Editor's Highlights—February 2026. International Journal of Dermatology. https://doi.org/10.1111/ijd.70248
Vancouver
Kemény L. Editor's Highlights—February 2026. International Journal of Dermatology. 2026. doi:10.1111/ijd.70248
BibTeX
@article{Kemny2026,
author = {Kemény, Lajos},
title = {Editor's Highlights—February 2026},
journal = {International Journal of Dermatology},
year = {2026},
doi = {10.1111/ijd.70248}
}
EUVIMED